Phase II trial of radiotherapy after hyperbaric... (2012 study) Skip to main content
Clinical Trial Int J Radiat Oncol Biol Phys 2012

Phase II trial of radiotherapy after hyperbaric oxygenation with multiagent chemotherapy (procarbazine, nimustine, and vincristine) for high-grade gliomas: long-term results

Ogawa K, Ishiuchi S, Inoue O, Yoshii Y, Saito A, Watanabe T, et al., Int J Radiat Oncol Biol Phys, 2012

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers gave adults with high-grade brain tumours (gliomas) radiotherapy right after a hyperbaric oxygen session, together with three chemotherapy drugs, and followed them over the long term.

What They Found

In a Phase II clinical trial of 57 adults with high-grade gliomas, radiotherapy given right after hyperbaric oxygen (HBO) plus chemotherapy was completed by all patients, and median overall survival was 20.2 months for the whole group. Survival was 17.2 months for the 39 patients with glioblastoma and 113.4 months for the 18 patients with Grade 3 gliomas. Tumour grade was the only significant factor linked to survival (p less than 0.001). No patient had neutropenic fever or intracranial hemorrhage, and no serious non-blood-related or late toxicities were seen. Twelve patients were still alive at a median follow-up of 62.0 months.

What This Means for Canadian Patients

For people with high-grade gliomas, this trial shows that radiotherapy (60 Gy in daily 2 Gy fractions) delivered less than 15 minutes after HBO, with chemotherapy, could be completed and had few serious side effects. The trial had no comparison group, so it cannot show whether HBO changed survival. Survival in glioblastoma was much shorter than in Grade 3 gliomas. Anyone considering this approach should discuss it with their cancer care team.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

This was a single-group Phase II trial with no comparison group, so the abstract cannot show that HBO improved survival, and only 12 of the 57 patients were alive at the last follow-up.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Clinical Trial
Category Radiation Injury
Source Pubmed
PubMed ID 21420247
Year Published 2012
Journal Int J Radiat Oncol Biol Phys
MeSH Terms Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Hyperbaric Oxygenation; Male; Middle Aged; Multivariate Analysis; Nimustine; Procarbazine; Radiation Tolerance; Supratentorial Neoplasms; Vincristine; Young Adult

Cite This Study

Share

This study relates to Delayed Radiation Injury. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Radiation Injury

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: March 19, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology